Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.410
-0.010 (-0.70%)
Apr 23, 2026, 1:04 PM EDT - Market open
Akebia Therapeutics Revenue
In the year 2025, Akebia Therapeutics had annual revenue of $236.20M with 47.46% growth. Akebia Therapeutics had revenue of $57.62M in the quarter ending December 31, 2025, with 23.93% growth.
Revenue (ttm)
$236.20M
Revenue Growth
+47.46%
P/S Ratio
1.61
Revenue / Employee
$1,217,505
Employees
194
Market Cap
377.74M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 236.20M | 76.02M | 47.46% |
| Dec 31, 2024 | 160.18M | -34.44M | -17.70% |
| Dec 31, 2023 | 194.62M | -97.86M | -33.46% |
| Dec 31, 2022 | 292.48M | 80.83M | 38.19% |
| Dec 31, 2021 | 211.65M | -82.99M | -28.17% |
| Dec 31, 2020 | 294.64M | -40.36M | -12.05% |
| Dec 31, 2019 | 335.00M | 127.26M | 61.26% |
| Dec 31, 2018 | 207.74M | 26.52M | 14.63% |
| Dec 31, 2017 | 181.23M | 179.69M | 11,706.32% |
| Dec 31, 2016 | 1.54M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Emergent BioSolutions | 742.90M |
| Organogenesis Holdings | 564.17M |
| Esperion Therapeutics | 403.14M |
| Evolus | 297.18M |
| Ironwood Pharmaceuticals | 296.15M |
| Aurora Cannabis | 272.13M |
| Canopy Growth | 203.04M |
| Kamada | 180.46M |
AKBA News
- 10 days ago - Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 - GlobeNewsWire
- 16 days ago - Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium - GlobeNewsWire
- 20 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 21 days ago - Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors - GlobeNewsWire
- 4 weeks ago - Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 - GlobeNewsWire
- 7 weeks ago - Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights - GlobeNewsWire
- 2 months ago - Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights - GlobeNewsWire